Big Pharma Outbids Public Investors: Step-Ups in Biopharma Exits
This article was originally published in Start Up
Executive SummaryBiotechs exiting via selling out to Big Pharma have been averaging far higher multiples than those exiting via IPO.
You may also be interested in...
Public Company Edition: Grossing $276m, Gossamer would have been the third-largest biopharma IPO in the US if it had launched last year. Also, recent public company financings include debt and follow-on offerings; and two more firms cut jobs – Capricor and Seres.